title: Safety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patients.
abstract: Iron sucrose and low-molecular-weight iron dextran (LMW-ID), two commonly used iron solutions, have been compared in terms of allergic adverse event profiles to date. However, the safety of total dose infusion of LMW-ID has been investigated by only one study in chronic kidney disease (CKD) (not dialysis) patients. Thus, we aimed to compare adverse event profiles of total and high-dose LMW-ID and iron sucrose infusions in a heterogenous renal patient group comprising CKD, hemodialysis, and peritoneal dialysis. In this retrospective chart review study, we included 110 predialysis CKD, 101 peritoneal dialysis, and 118 hemodialysis patients. We included a total of 329 patients who were administered parenteral iron sucrose or LMW-ID between September 2006 and April 2010. Adverse events were determined both by medical and nursing follow-up notes. Laboratory data and clinical characteristics were collected from patient charts. Adverse event rates were compared between iron sucrose and LMW-ID infusions. In a total of 329 patients, 530 infusions (3470 ampules) were administered. We detected adverse reaction in only 1 patient. This adverse reaction, which manifested as generalized pruritus, occurred in a patient who received 500 mg of iron sucrose infusion. There were neither anaphylactic reactions nor deaths associated with infusion of either preparation. We did not observe any other adverse event related to administration of 500 and 1000 mg of iron sucrose at single infusion. The results of this study showed comparable safety of total dose LMW-ID and high-dose iron sucrose in a heterogenous group of renal patients.
authors.affiliation: Nephrology Department, Selcuk University, Meram School of Medicine, Meram, Konya, Turkey.
authors.forename: Huseyin
authors.initials: H
authors.lastname: Atalay
authors.forename: Yalcin
authors.initials: Y
authors.lastname: Solak
authors.forename: Kadir
authors.initials: K
authors.lastname: Acar
authors.forename: Nilgun
authors.initials: N
authors.lastname: Govec
authors.forename: Suleyman
authors.initials: S
authors.lastname: Turk
mesh_terms: D000328:Adult; D000368:Aged; D002908:Chronic Disease; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077605:Ferric Oxide, Saccharated; D005500:Follow-Up Studies; D005937:Glucaric Acid; D006397:Hematinics / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007505:Iron-Dextran Complex / Q000008:administration & dosage / Q000009:adverse effects; D007674:Kidney Diseases / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D012189:Retrospective Studies
chemical_list: D005290:Ferric Compounds; D006397:Hematinics; D007505:Iron-Dextran Complex; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid